Combining FHD-286 with decitabine, a bromodomain and extra-terminal domain (BET) inhibitor, a menin inhibitor or venetoclax significantly enhanced acute myeloid leukemia cell lethality in vitro in a synergistic manner. The gene discussed is MEN1; the disease is acute myeloid leukemia.